公开(公告)号：US20240409657A1

公开(公告)日：2024-12-12

申请号：US18814259

申请日：2024-08-23

Applicant: Genentech, Inc.

Inventor： Matthew Dominic CASCINO

IPC: C07K16/28 ,  A61K31/138 ,  A61K31/167 ,  A61K31/34 ,  A61K31/5377 ,  A61K31/573 ,  A61K39/00 ,  A61K39/395 ,  A61P37/06

Abstract: The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.

公开(公告)号：US20220259321A1

公开(公告)日：2022-08-18

申请号：US17691356

申请日：2022-03-10

Applicant: Genentech, Inc.

Inventor： Matthew Dominic CASCINO

IPC: C07K16/28 ,  A61P37/06 ,  A61K39/395 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/138 ,  A61K31/167

Abstract: The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.

公开(公告)号：US20230039927A1

公开(公告)日：2023-02-09

申请号：US17816946

申请日：2022-08-02

Applicant: Genentech, Inc.

Inventor： Matthew Dominic CASCINO

IPC: C07K16/28 ,  A61P37/06 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/138 ,  A61K31/167 ,  A61K39/395 ,  A61K39/00

Abstract: The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.

公开(公告)号：US20230287133A1

公开(公告)日：2023-09-14

申请号：US18055522

申请日：2022-11-15

Applicant: Genentech, Inc.

Inventor： Susan Lee LIMB ,  Matthew Dominic CASCINO ,  Monique NICOLL ,  Jay Prakash GARG ,  Michael Zecong LIAO

IPC: C07K16/28 ,  A61K31/573 ,  A61P37/06

CPC classification number: C07K16/2887 ,  A61K31/573 ,  A61P37/06

Abstract: Disclosed herein are compositions and methods for the treatment of systemic lupus erythematosus using anti-CD20/anti-CD3 bispecific antibodies, such as mosunetuzumab.